TOP TEN perturbations for Q13163 (Homo sapiens)

Organism: Homo sapiens
Gene: Q13163
Selected probe(set): 211370_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q13163 (211370_s_at) across 5217 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.7034636
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

formaldehyde study 3 (4500ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):-2.2374058
Number of Samples:3 / 3
Experimental formaldehyde study 3 (4500ug/ml)
Bronchial epithelial cells (NHBE) treated with 4500 ug/ml formaldehyde (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker.

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):2.0275288
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-2.0189419
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-1.7167645
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 ?g/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):1.7016068
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):1.6523504
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-? agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):1.6126442
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-1.5519772
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):1.4333353
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ? 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.